JAAPA CME Post-Test June 2023
An Update on Treatments for Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) is less common than primary hypertension or diabetes but should be considered as a possible cause of end-stage renal disease, especially in young patients without comorbidities. Because of ADPKD’s nonspecific symptoms, the diagnosis, treatment, and pertinent patient education may be delayed. This activity describes ADPKD and its management, including tolvaptan, a new treatment with the potential to reduce or delay morbidity. However, only a subset of patients qualifies for this expensive treatment.
- Describe the pathophysiology, clinical presentation, differential diagnoses, diagnostic studies, lifestyle modifications, and complications of ADPKD
- Describe the importance of hypertension management to reduce renal dysfunction and cardiovascular complications associated with ADPKD
- Outline the indication, mechanism of action, adverse effects, and contraindications of tolvaptan treatment
- Describe the 10 steps for prescribing tolvaptan to a high-risk patient with ADPKD
An Overview of Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) can present as a cytopenia—often as unexplained anemia. Because MDS can progress to acute myelogenous leukemia, primary care providers should be aware of the signs and symptoms, which are associated with the corresponding cytopenia that patients experience and may include fatigue, infection, easy bruising, and bleeding. Treatment options center on managing related cytopenias. The only cure, stem cell transplant, is not readily available.
- Recognize the clinical presentation of MDS including key diagnostic criterion
- Describe the basic pathophysiology of MDS
- Understand the treatment options for MDS
AAPA offers no returns or refunds for online CME activities purchased via the AAPA store. All sales are final.